Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Sol-Gel Technologies Ltd. director Gottfried Ran filed an initial Form 3 showing his equity stake in the company. He directly holds 1,550 Ordinary Shares and two stock option grants over 4,500 and 7,500 Ordinary Shares, with exercise prices of 100.2000 and 12.0000, expiring on February 2, 2031 and January 9, 2034, respectively.
One option is fully vested, while the other vested 33.33% on February 28, 2025 and continues to vest in equal quarterly installments over two years, subject to his continued service as a director.
Sol-Gel Technologies Ltd. director Sharon Kochan reported existing derivative holdings in an initial ownership statement. The filing lists a stock option to buy 7,500 Ordinary Shares at an exercise price of $12.0000 per share, expiring on January 9, 2034.
The option vested as to 33.33% of the underlying Ordinary Shares on February 28, 2025 and is scheduled to vest in equal quarterly installments over the following two years, conditioned on continued service as a director. All 7,500 underlying shares are reported as directly held through this option position.
Sol-Gel Technologies Ltd. director Yanai Yuval has reported initial beneficial ownership of a stock option to buy Ordinary Shares. The option covers 7,500 underlying Ordinary Shares at an exercise price of $12.0000 per share and expires on January 9, 2034.
According to the vesting terms, 33.33% of the option vested on February 28, 2025, with the remaining Ordinary Shares vesting in equal quarterly installments over the following two years, subject to his continued service as a director.
Sol-Gel Technologies Ltd. director Hanna Lerman reports holding a fully vested stock option to buy 2,031 ordinary shares at an exercise price of 55.6600. The option relates to ordinary shares with NIS 1.00 par value per share and expires on 2027-07-13.
Sol-Gel Technologies Ltd. director Arkin Itai Gidon filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company but does not report any buy, sell, or other share transactions in this submission.
Sol-Gel Technologies Ltd. executive Michael Glezin, the Chief Business Officer, has filed an initial ownership report showing his holdings in the company’s ordinary shares and stock options. This Form 3 does not reflect new trades but discloses his current equity position.
Glezin directly holds 1,500 Ordinary Shares and several stock option awards over ordinary shares. These options cover 2,500 shares at an exercise price of $49.80 expiring on November 2, 2032, 5,000 shares at $8.96 expiring on February 18, 2035, and 7,500 shares at $69.50 expiring on January 19, 2036. Footnotes state that each option vests 25% on a specified initial date, with the remaining 75% vesting in equal quarterly installments over three years, subject to his continued service.
Sol-Gel Technologies Ltd. executive Ofra Levy-Hacham, VP Clinical, Regulatory & Quality, filed an initial Form 3 reporting her beneficial ownership of several stock option grants over the company’s ordinary shares. These options are held directly, with exercise prices ranging from $8.96 to $100.00 per share and expiration dates between August 2026 and February 2035.
According to the filing, some of the options are already fully vested, while others began vesting 25% on specific dates in 2023, 2024, and 2026 and will continue to vest in equal quarterly installments over the following three years, subject to her continued service with the company.
Sol-Gel Technologies Ltd. executive Ofer Toledano, VP Research & Development, filed an initial insider ownership report. He directly holds 1,461 Ordinary Shares and a series of stock options over Ordinary Shares with exercise prices ranging from 8.9600 to 100.0000, expiring between 2026 and 2035. Several options are already fully vested, while others vest in quarterly installments over three years, contingent on continued service.
Sol-Gel Technologies Ltd. Chairman and CEO Moshe Arkin filed an initial ownership report showing his stake in the company. He reports indirect ownership of warrants giving the right to buy 200,000 ordinary shares at an exercise price of $58.50 per share, expiring on January 27, 2028, through M. Arkin Dermatology Ltd. He also reports 143,257 ordinary shares held directly and 1,606,856 ordinary shares held indirectly through M. Arkin Dermatology Ltd. A footnote states he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
SLGL filed a Form 144 reporting proposed sales of Ordinary shares under an Employee Stock Option Plan, to be settled for cash upon exercise.
The excerpt lists two dispositions by Yosef Itzik during the past three months: 1,168 Ordinary shares on 01/07/2026 for $70,250.51 and 2,726 Ordinary shares on 02/23/2026 for $240,192.00. The filing references Nasdaq and Ordinary share class.